Estuary Launches with $103 Million for Kidney Gene Therapy

Company Estuary Biotherapeutics Event Type Company Launch and Financing (Series A plus Seed) Modality AAV gene therapy; local (focal kidney-directed) delivery Asset EST-201 (PKD2); EST-101 (PKD1 functional region) Target PKD2; PKD1 (polycystin-1 functional region) Disease Area Autosomal dominant polycystic kidney disease (ADPKD) Summary Estuary Biotherapeutics…